Podium to Practice: ESMO® 2026 – GI: PRABITAS
OR
Studies / Trials Discussed
LBA31 – Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial
Chair
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
LBA31 – Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.